Skip to main content

Advertisement

SpringerLink
Log in

Identification, Diagnosis and Treatment of Heparin-induced Thrombocytopenia and Thrombosis: A Registry of Prolonged Heparin Use and Thrombocytopenia among Hospitalized Patients with and without Cardiovascular Disease

The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry Steering Committee

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Background: Heparin-induced thrombocytopenia (HIT) is estimated to occur in 1–5% of all patients receiving heparin, and 25–50% of such cases develop heparin-induced thrombocytopenia with thrombosis (HITT) A conservative estimate based only on cardiovascular patients suggests that in the United States approximately 100,000 patients develop thrombocytopenia, and 25–50,000 develop HITT annually. Both HIT and HITT are associated with high morbidity and mortality and represent substantial worldwide public health concerns.

Registry Design: The objective of the Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry is to identify the incidence of HIT and/or HITT in patients treated with systemic heparin (unfractionated or low molecular weight heparin) in contemporary practice. Additional objectives include to: (1) provide a comprehensive database of patients with suspected HIT or HITT, (2) monitor and define clinical events, including thrombocytopenia, thrombosis, and mortality among patients treated with prolonged (> 96 hours) heparin, (3) describe the incidence and outcomes of HIT and HITT in patients who are treated with heparin and who develop thrombocytopenia in the Coronary Care Unit setting, and (4) document and characterize current diagnostic and therapeutic strategies of suspected HIT. The unblinded registry will record approximately 5,000 patients at 60–80 US hospitals with either prolonged systemic heparin administration or thrombocytopenia and those with suspected HIT or HITT. Enrollment began in the first quarter 2003 and was completed at the end of 2004.

Implications: The registry will provide valuable insights to the incidence and consequences of HIT and HITT that will enable improvements in diagnosis and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Spencer FA. Heparin-induced thrombocytopenia: Patient profiles and clinical manifestations. J Thromb Thrombolysis 2000;10:S21–S25.

    Article  Google Scholar 

  2. Walenga JM, Jeske WP, Messmore HL. Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. J Thromb Thrombolysis 2000;10:S13–S20.

    Article  Google Scholar 

  3. Lubenow N, Greinacher A. Management of patients with heparin-induced thrombocytopenia: Focus on recombinant hirudin. J Thromb Thrombolysis 2000;10:S47–S57.

    Article  CAS  Google Scholar 

  4. Weissman RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. Arch Surg 1958;76:219–227.

    Google Scholar 

  5. Roberts B, Rosato FE, Rosato EF. Heparin—a cause of arterial emboli? Surgery 1964;55:803–808.

    CAS  PubMed  Google Scholar 

  6. Natelson EA, Lynch EC, Alfrey CP Jr, Gross JB. Heparin-induced thrombocytopenia. An unexpected response to treatment of consumption coagulopathy. Ann Intern Med 1969;71:1121–1125.

    CAS  PubMed  Google Scholar 

  7. Fratantoni JC, Pollet R, Gralnick HR. Heparin-induced thrombocytopenia: Confirmation of diagnosis with in vitro methods. Blood 1975;45:395–401.

    CAS  PubMed  Google Scholar 

  8. Babcock RB, Dumper CW, Scharfman WB. Heparin-induced thrombocytopenia. N Engl J Med 1976;295:237–241.

    CAS  PubMed  Google Scholar 

  9. Bell WR, Tomasulo PA, Alving BM, Duffy TP. Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients. Ann Intern Med 1976;85:155–160.

    CAS  PubMed  Google Scholar 

  10. Bell WR, Royall RM. Heparin-associated thrombocytopenia: A comparison of three heparin preparations. N Engl J Med 1980;303:902–907.

    CAS  PubMed  Google Scholar 

  11. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973;136:409–416.

    CAS  PubMed  Google Scholar 

  12. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia: Eight cases with thrombotic-hemorrhagic complications. Ann Surg 1977;186:752–758.

    CAS  PubMed  Google Scholar 

  13. Nelson JC, Lerner RG, Goldstein R, Cagin NA. Heparin-induced thrombocytopenia. Arch Int Med 1978;138:548–552.

    Article  CAS  Google Scholar 

  14. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia (letter). Thromb Haemost 1992;68:95–96.

    CAS  PubMed  Google Scholar 

  15. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, Eds., Heparin-Induced Thrombocytopenia, 2nd ed. New York, NY: Marcel Dekker, 2000:231–269.

  16. Warkentin TE. Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med 2000;6:343–351.

    Article  CAS  PubMed  Google Scholar 

  17. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502–507.

    Article  CAS  PubMed  Google Scholar 

  18. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804–812.

    CAS  PubMed  Google Scholar 

  19. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002;136:210–215.

    PubMed  Google Scholar 

  20. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001;135:502–506.

    CAS  PubMed  Google Scholar 

  21. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: Focus on lepirudin. Circulation 2001;103:1479–1484.

    CAS  PubMed  Google Scholar 

  22. Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F; ARG-216/310/311 Study Investigators. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177–184.

    Article  PubMed  Google Scholar 

  23. Rice L, Nguyen P, Vann A. Preventing complications in heparin-induced thrombocytopenia. Alternative anticoagulants are improving patient outcomes. Postgrad Med 2002;112:85–89.

    Google Scholar 

  24. Kelton JG. Heparin-induced thrombocytopenia: An overview. Blood Reviews 2002;16:77–80.

    Article  CAS  PubMed  Google Scholar 

  25. Reilly MP, Taylor SM, Hartman NK, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood 2001;98:2442–2447.

    Article  CAS  PubMed  Google Scholar 

  26. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemost 1995;73:21–28.

    CAS  PubMed  Google Scholar 

  27. Harrington RA, Sane DC, Califf RM, et al., for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1994;23:891–898.

    CAS  PubMed  Google Scholar 

  28. Eikelboom JW, Anand SS, Mehta SR, et al. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation. Circulation 2001;103:643–650.

    CAS  PubMed  Google Scholar 

  29. Berkowitz SD, Sane DC, Sigmon KN, et al. RM for the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol 1998;32:311–319.

    Article  CAS  PubMed  Google Scholar 

  30. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (Abciximab) therapy. Circulation 1997;95:809–813.

    CAS  PubMed  Google Scholar 

  31. Kereiakes DJ, Berkowitz SD, Lincoff AM, et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J 2000;140:74–80.

    Article  CAS  PubMed  Google Scholar 

  32. Sane DC, Damaraju LV, Topol EJ, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000;36:75–83.

    Article  CAS  PubMed  Google Scholar 

  33. McClure MW, Berkowitz SD, Sparapani R, et al., for the PURSUIT Investigators. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Experience. Circulation 1999;99:2892–2900.

    CAS  PubMed  Google Scholar 

  34. Williams RT, Damaraju LV, Mascelli MA, et al. Anti-platelet factor 4/heparin antibodies: An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 2003;107:2307–2312.

    Article  PubMed  Google Scholar 

  35. Greinacher A, Janssens U, Berg G, et al., for the Heparin-Associated Thrombocytopenia Study (HAT) Investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587–593.

    CAS  PubMed  Google Scholar 

  36. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106:629–635.

    Article  CAS  PubMed  Google Scholar 

  37. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286–1292.

    Article  CAS  PubMed  Google Scholar 

  38. Warkentin TE. Laboratory testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis 2000;10:S35–S45.

    Article  CAS  Google Scholar 

  39. The Direct Thrombin Inhibitor Trialists’ Collaborative Group. Direct thrombin inhibitors in acute coronary syndrome: Principal results of a meta-analysis based on individual patients’ data. Lancet 2002;359:294–302.

    Google Scholar 

  40. Campbell KR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol2000;12:14F–19F.

    PubMed  Google Scholar 

  41. Schiele F, Vuillemenot A, Kramarz P, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995;50:20–25.

    CAS  PubMed  Google Scholar 

  42. Greinacher A, Volpel H, Janssens U, et al., for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999;99:73–80.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Division of Hematology, and School of Pharmacy, University of North Carolina, Chapel Hill, NC

    E. Magnus Ohman MD, Stephan Moll MD & Jo E. Rodgers PharmD

  2. Division of Cardiology, Division of Pulmonary Medicine and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC

    Christopher B. Granger MD, Richard C. Becker MD, Peter B. Berger MD, Victor F. Tapson MD, Peter Sinnaeve MD & Kevin J. Anstrom

  3. Hematology-Oncology Section and Section of Cardiology, Baylor College of Medicine and Methodist Hospital, Houston, TX; 4Hematology/Oncology Division, University of Pennsylvania School of Medicine, Philadelphia, PA

    Lawrence Rice MD & Neal S. Kleiman MD

  4. Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky

    Charles S. Abrams MD

  5. Division of Cardiology, UNC-Chapel Hill, CB #7075, Chapel Hill, NC, 27599-7075

    David Moliterno MD & Stephen S. Steinhubl MD

Authors
  1. E. Magnus Ohman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher B. Granger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence Rice MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charles S. Abrams MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Richard C. Becker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter B. Berger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Neal S. Kleiman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David Moliterno MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Stephan Moll MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jo E. Rodgers PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Stephen S. Steinhubl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Victor F. Tapson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Peter Sinnaeve MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kevin J. Anstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Magnus Ohman MD.

Additional information

The CATCH Registry is supported by a grant from Berlex Laboratories, Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohman, E.M., Granger, C.B., Rice, L. et al. Identification, Diagnosis and Treatment of Heparin-induced Thrombocytopenia and Thrombosis: A Registry of Prolonged Heparin Use and Thrombocytopenia among Hospitalized Patients with and without Cardiovascular Disease. J Thromb Thrombolysis 19, 11–19 (2005). https://doi.org/10.1007/s11239-005-0850-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-005-0850-7

Search

Navigation